Validation and Advanced Development of Emerging Technologies in Biospecimen Science (R33)

The summary for the Validation and Advanced Development of Emerging Technologies in Biospecimen Science (R33) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Validation and Advanced Development of Emerging Technologies in Biospecimen Science (R33): Purpose. This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications proposing technically innovative feasibility studies focused on the advanced development and validation of cancer-relevant technologies that address the issues related to pre-analytical variations in the collection, processing, handling, and storage of biospecimens or its derivatives. The overall goal is to develop technologies capable of interrogating and/or maximizing the quality and utility of biospecimens or their derived samples for downstream molecular analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. This FOA solicits R33 applications; this mechanism is suitable for projects where proof-of-principle of the proposed technology or methodology has already been established and supportive preliminary data are available. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued is an example of a topic not appropriate for this solicitation and will be returned as non-responsive. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. Mechanism of Support. This FOA will utilize the R33 grant mechanism and runs in parallel with a FOA of identical scientific scope, RFA-CA-10-001 that solicits applications under the NIH Exploratory/Developmental R21 grant mechanism.
Federal Grant Title: Validation and Advanced Development of Emerging Technologies in Biospecimen Science (R33)
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-CA-10-002
Type of Funding: Grant
CFDA Numbers: 93.393
CFDA Descriptions: Cancer Cause and Prevention Research
Current Application Deadline: Sep 30, 2010
Original Application Deadline: Sep 30, 2010
Posted Date: Oct 26, 2009
Creation Date: Oct 26, 2009
Archive Date: Oct 31, 2010
Total Program Funding: $2,250,000
Maximum Federal Grant Award: $300,000
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments - Public and State controlled institutions of higher education - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Non-domestic (non-U.S.) Entities (Foreign Organizations); U.S. Territory or Possession.
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants
Provocative Questions (PQs) in Multiple Myeloma Disparities Research (R21 Clinical Trial O...
Provocative Questions (PQs) in Multiple Myeloma Disparities Research (R01 Clinical Trial O...
Exploratory Grants in Cancer Epidemiology (R21 Clinical Trial Optional)
Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Aggress...
U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (HIV/AIDS) (U01 ...
Pilot Studies in Pancreatic Cancer
Cancer Prevention Research Small Grant Program
Molecular Targets for Nutrients in Prostate Cancer Prevention
More Grants from the National Institutes of Health
Drug Screening with Biofabricated 3-D Skin Disease Tissue Models (U18 Clinical Trial Not A...
Postdoctoral Research Associate Training (PRAT) Program (Fi2)
Methods to Improve Reproducibility of Human iPSC Derivation, Growth and Differentiation (S...
Sponsored Programs Administration Development (SPAD) Program (UC2 - Clinical Trial Not All...
PrEP for HIV Prevention among Substance Using Populations (R01 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com